

CITATION REPORT

List of articles citing

Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon- β (MIRACLE trial): study protocol for a randomized controlled trial

DOI: 10.1186/s13063-017-2427-0
Trials, 2018, 19, 81.

Source: <https://exaly.com/paper-pdf/71526231/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
204	Drug Repurposing for Viral Infectious Diseases: How Far Are We?. 2018 , 26, 865-876		148
203	Molecular Pathogenesis of Middle East Respiratory Syndrome (MERS) Coronavirus. 2019 , 6, 139-147		14
202	A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). 2019 , 30, 9-18		84
201	Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections. 2019 , 10, 1327		57
200	Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections. 2019 , 11,		112
199	The Middle East Respiratory Syndrome (MERS). 2019 , 33, 891-905		143
198	Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection. 2019 , 19, 870		30
197	[Coronaviruses as the cause of respiratory infections]. 2019 , 60, 1136-1145		90
196	Nucleoside analogues for the treatment of coronavirus infections. 2019 , 35, 57-62		101
195	Broad-spectrum coronavirus antiviral drug discovery. 2019 , 14, 397-412		109
194	Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. 2019 , 167, 45-67		92
193	Contemporary Concise Review 2018: Respiratory infections and tuberculosis. 2019 , 24, 598-604		3
192	Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling. 2019 , 27, 1981-1989		17
191	Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study. 2020 , 70, 1837-1844		166
190	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. 2020 , 11, 222		1059
189	Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon- β (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. <i>Trials</i> , 2020 , 21, 8	2.8	88
188	Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics. 2020 , 85, 104583		5

187	Interferon β 1b in treatment of severe COVID-19: A randomized clinical trial. 2020 , 88, 106903	82
186	Discovery of human coronaviruses pan-papain-like protease inhibitors using computational approaches. 2020 , 10, 546-559	35
185	Novel hybrid antiviral VTRRT-13V2.1 against SARS-CoV2 main protease: retro-combinatorial synthesis and molecular dynamics analysis. 2020 , 6, e05122	4
184	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. 2020 , 1-24	11
183	Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. 2020 , 56, 106143	51
182	Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome. 2020 , 383, 1645-1656	38
181	Immuno-pathogenesis of nCOVID-19 and a possible host-directed therapy including anti-inflammatory and anti-viral prostaglandin (PG J) for effective treatment and reduction in the death toll. 2020 , 143, 110080	2
180	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. 2020 , 74, 109721	63
179	A Randomized Clinical Trial of the Efficacy and Safety of Interferon β 1a in Treatment of Severe COVID-19. 2020 , 64,	170
178	A Hypothesis for the Possible Role of Zinc in the Immunological Pathways Related to COVID-19 Infection. 2020 , 11, 1736	26
177	Current strategies against COVID-19. 2020 , 15, 70	7
176	FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. 2020 , 53, 100719	79
175	Guidance for the management of adult patients with coronavirus disease 2019. 2020 , 133, 1575-1594	16
174	Comprehensive Literature Review and Evidence evaluation of Experimental Treatment in COVID 19 Contagion.. 2020 , 14, 1179548420964140	3
173	From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic. 2020 , 44, 509-512	78
172	Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. 2020 , 7, 581521	23
171	Coronavirus and Homo Sapiens in Coronavirus Disease 2019 (COVID-19). 2020 , 4, 121-131	
170	COVID-19: A review of the proposed pharmacological treatments. 2020 , 886, 173451	54

169	Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. 2020 , 11, 1949	163
168	An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. 2020 , 144, 111639	28
167	SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. 2020 , 19, 40	62
166	Drug repurposing approach to fight COVID-19. 2020 , 72, 1479-1508	165
165	The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019. 2020 , 18, 359	15
164	Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. 2020 , 10, e041437	24
163	COVID-19 in Children: Present and Future Perspective, An Interim Review. 2020 , 10, e53-e62	3
162	A Review on Novel Drug Targets and Future Directions for COVID-19 Treatment. 2020 , 14, 77-82	9
161	COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management. 2020 , 11, 563478	30
160	What are the drugs having potential against COVID-19?. 2020 , 1-21	4
159	A Narrative Review of Emerging Therapeutics for COVID-19. 2020 , 4, 745-758	5
158	The preliminary comparative results between Covid-19 and non-Covid-19 patients in Western China. 2020 , 20, 935	4
157	SARS-CoV-2: A critical review of its history, pathogenesis, transmission, diagnosis and treatment. 2020 , 2, 217-225	12
156	Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology. 2020 , 20, 559-570	5
155	Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. 2020 , 19, 102567	375
154	Current targeted therapeutics against COVID-19: Based on first-line experience in China. 2020 , 157, 104854	27
153	Human Coronavirus Infections Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and SARS-CoV-2. 2020 ,	11
152	Clinical trials on drug repositioning for COVID-19 treatment. 2020 , 44, e40	226

151	Coronavirus Pandemic-Therapy and Vaccines. 2020 , 8,	37
150	Mysterious Virus: A Review on Behavior and Treatment Approaches of the Novel Coronavirus, 2019-nCoV. 2020 , 51, 375-383	7
149	SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the culprit lesion of ARDS onset? What is there besides Tocilizumab? SGP130Fc. 2020 , 2, 100029	102
148	A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). 2020 , 158, 104929	53
147	Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring. 2020 , 45, 1199-1205	8
146	Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors. 2020 , 56, 106055	44
145	Merits and culprits of immunotherapies for neurological diseases in times of COVID-19. 2020 , 56, 102822	11
144	COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. 2020 , 286, 198070	75
143	Novel therapeutic approaches for treatment of COVID-19. 2020 , 98, 789-803	27
142	The broad-spectrum antiviral recommendations for drug discovery against COVID-19. 2020 , 52, 408-424	12
141	Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. 2020 , 34, 1597-1602	34
140	A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. 2020 , 382, 1787-1799	3303
139	COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. 2020 , 16, 1232-1238	310
138	Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). 2020 , 46, 854-887	1011
137	The SARS-CoV-2 outbreak: What we know. 2020 , 94, 44-48	559
136	2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. 2020 , 9, 19	192
135	Middle East respiratory syndrome. 2020 , 395, 1063-1077	245
134	Covid-19: current knowledge, disease potential, prevention and clinical advances. 2020 , 44, 121-131	8

133	Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives. 2020 , 9,	44
132	Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis. 2020 , 86, 106740	3
131	Coronavirus Disease 2019-COVID-19. 2020 , 33,	386
130	COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection. 2020 , 9,	77
129	A Perspective on Emerging Therapeutic Interventions for COVID-19. 2020 , 8, 281	33
128	Cyclophilin inhibitors restrict Middle East respiratory syndrome coronavirus interferon- λ in mice. 2020 , 56,	9
127	Middle East Respiratory Syndrome Coronavirus and Severe Acute Respiratory Syndrome Coronavirus. 2020 , 41, 568-578	9
126	First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan. 2020 , 119, 747-751	121
125	Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child. 2020 , 52, 419-422	51
124	A Novel Coronavirus (COVID-19) Outbreak: A Call for Action. 2020 , 157, e99-e101	42
123	The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. 2020 , 22, 80-85	198
122	The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?. 2020 , 49, 717-726	775
121	Public awareness of coronavirus in Al-Jouf region, Saudi Arabia. 2020 , 29, 1-8	33
120	Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 2020 , 395, 497-506	25240
119	Drug treatment options for the 2019-new coronavirus (2019-nCoV). 2020 , 14, 69-71	654
118	Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. 2020 , 16, 240-246	301
117	Going global - Travel and the 2019 novel coronavirus. 2020 , 33, 101578	164
116	Type 1 interferons as a potential treatment against COVID-19. 2020 , 178, 104791	333

115	Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. 2020 , 53, 488-492	60
114	Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. 2020 , 64, 254-269	265
113	Current pharmacological treatments for COVID-19: What's next?. 2020 , 177, 4813-4824	137
112	[From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic]. 2020 , 44, 509-512	3
111	2019 Novel coronavirus (COVID-19) overview. 2020 , 1-9	16
110	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities. 2020 , 5, 501-517	9
109	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities. 2020 , 2, 254-269	8
108	Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms. 2020 , 59, 1769-1779	132
107	Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase. 2021 , 39, 3771-3779	18
106	Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps. 2021 , 30, 51-58	3
105	Potential role of interferons in treating COVID-19 patients. 2021 , 90, 107171	36
104	SARS-COV-2 (COVID-19): Cellular and biochemical properties and pharmacological insights into new therapeutic developments. 2021 , 39, 10-28	5
103	Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19. 2021 , 64, 30-35	6
102	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of , , and clinical trials. 2021 , 11, 1207-1231	17
101	Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia. 2021 , 102, 303-309	4
100	Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial. 2021 , 81, 153367	17
99	Probable positive effects of the photobiomodulation as an adjunctive treatment in COVID-19: A systematic review. 2021 , 137, 155312	18
98	COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. 2021 , 49, 199-213	46

97	Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis. 2021 , 11, 45-52	22
96	COVID-19-Directed Medications. 2021 , 171-179	
95	Identification of novel inhibitors of angiotensin-converting enzyme 2 (ACE-2) receptor from <i>Urtica dioica</i> to combat coronavirus disease 2019 (COVID-19). 2021 , 25, 1795-1809	4
94	Therapeutics and Vaccines: Strengthening Our Fight Against the Global Pandemic COVID-19. 2021 , 78, 435-448	4
93	Transmission, diagnosis, and treatment of coronavirus disease 2020: a review. 381-386	
92	Prediction of repurposed drugs for Coronaviruses using artificial intelligence and machine learning. 2021 , 19, 3133-3148	5
91	Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review. 2021 , 23, 5	8
90	Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. 2020 , 11, 616595	8
89	Development of A MERS-CoV Replicon Cell Line for Antiviral Screening. 2021 , 36, 730-735	0
88	Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). 2021 , 27, 115-126	7
87	COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. 2021 , 8, 606755	2
86	network-based analysis of drugs used against COVID-19: Human well-being study. 2021 , 28, 2029-2039	0
85	Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. 2021 , 172, 524-541	38
84	Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19. 2021 , 77, 1297-1307	2
83	The effects of combination of and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19 outpatients: a randomized controlled trial. 2021 ,	12
82	Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: An approach. 2021 , 11, 158-172	21
81	Recent Advances in the Discovery of Potent Proteases Inhibitors Targeting the SARS Coronaviruses. 2021 , 21, 307-328	0
80	Immunobiology and nanotherapeutics of severe acute respiratory syndrome 2 (SARS-CoV-2): a current update. 2021 , 53, 559-580	5

79	Current diagnostic and therapeutic strategies for COVID-19. 2021 , 11, 129-137	5
78	Computer-Aided Prediction and Identification of Phytochemicals as Potential Drug Candidates against MERS-CoV. 2021 , 2021, 1-7	5
77	An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- α and hydroxychloroquine in hospitalized patients with COVID-19. 2021 , 27, 1826-1837	27
76	Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies. 2021 , 110, 321-333	4
75	The Chronicle of COVID-19 and Possible Strategies to Curb the Pandemic. 2021 , 28, 2852-2886	9
74	A combination treatment of IFN- β and IFN- λ accelerates viral clearance and control inflammatory response in COVID-19: Preliminary results of a randomized controlled trial. 2021 , 001-014	1
73	Potential Drugs for the Treatment of COVID-19: Synthesis, Brief History and Application. 2021 , 13, 184-202	1
72	Focused role of nanoparticles against COVID-19: Diagnosis and treatment. 2021 , 34, 102287	10
71	SARS-CoV-2: Insight in genome structure, pathogenesis and viral receptor binding analysis - An updated review. 2021 , 95, 107493	12
70	Coronavirus Disease 2019 (COVID-19): Origin, Impact, and Drug Development.	1
69	An Overview of the Epidemiologic, Diagnostic and Treatment Approaches of COVID-19: What do We Know?. 2021 , 42, 1604061	2
68	Withdrawal Notice: Nanotechnology-Based Approaches and Investigational Therapeutics against COVID-19. 2021 ,	2
67	Coronavirus and its terrifying inning around the globe: The pharmaceutical cares at the main frontline. 2021 , 275, 129968	3
66	A dossier on COVID-19 chronicle. 2021 ,	2
65	Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-1) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in pregnancy - An overview. 2021 , 263, 171-175	2
64	Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. 2021 , 22,	20
63	2019 novel Coronavirus: current knowledge, cardiovascular implications and management. 2021 , 69, 377-388	
62	Severe Middle East Respiratory Syndrome (MERS) Pneumonia. 2022 , 362-372	1

61	Infectious disease immunotherapies [An update: Revisiting an age-old adage in times of COVID-19. 2021 , 23, 10	
60	Aspects of Epidemiology, Pathology, Virology, Immunology, Transmission, Prevention, Prognosis, Diagnosis, and Treatment of COVID-19 Pandemic: A Narrative Review. 2021 , 12, 38	1
59	Pharmacotherapeutics of SARS-CoV-2 Infections. 2021 , 16, 12-37	3
58	Hospital Preparedness for COVID-19: The Known and The Known Unknown. 2021 , 70, 25-34	5
57	MERS-CoV: epidemiology, molecular dynamics, therapeutics, and future challenges. 2021 , 20, 8	9
56	Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin. 2020 , 60, 815-825	40
55	Human Acute and Chronic Viruses: Host-Pathogen Interactions and Therapeutics. 2020 , 1-120	1
54	1,2,4 triazolo[1,5-a] pyrimidin-7-ones as novel SARS-CoV-2 Main protease inhibitors: In silico screening and molecular dynamics simulation of potential COVID-19 drug candidates. 2020 , 267, 106478	11
53	Review of trials currently testing treatment and prevention of COVID-19. 2020 , 26, 988-998	57
52	Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta. 2020 , 70, 291-297	10
51	Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). 2020 , 48, e440-e469	566
50	Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases.	31
49	Transmission and clinical characteristics of coronavirus disease 2019 in 104 outside-Wuhan patients, China.	4
48	Review and methodological analysis of trials currently testing treatment and prevention options for COVID-19 globally.	1
47	Clinical evaluation of IFN beta1b in COVID-19 pneumonia: a retrospective study.	10
46	Effect of combination of interferon alpha-2b and interferon-gamma or interferon alpha-2b alone for elimination of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.	11
45	Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19. 2020 , 15, 489-493	79
44	A narrative review on the basic and clinical aspects of the novel SARS-CoV-2, the etiologic agent of COVID-19. 2020 , 8, 1686	6

43	Current Scenario and Future Prospect in the Management of COVID-19. 2021 , 28, 284-307	13
42	SARS-CoV-2 / COVID-19 and its Transmission, Prevention, Treatment and Control - An Update. 2020 , 14, 945-956	1
41	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century. 2020 , 22, 432-450	29
40	A Generalized Overview of SARS-CoV-2: Where Does the Current Knowledge Stand?. 2020 , 17, em251	7
39	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. 2020 , 21,	25
38	Protocolo de manejo para la infecci3n por COVID-19. 2020 , 33, 43-52	2
37	Four cases of coronavirus disease 2019 in the early stage of pandemic of South Korea: a single public hospital experience. 2020 , 35, 788-792	1
36	Interim Guidelines on Antiviral Therapy for COVID-19. 2020 , 52, 281-304	23
35	Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use. 2020 , 151, 184-189	56
34	The saudi critical care society clinical practice guidelines on the management of COVID-19 patients in the intensive care unit. 2020 , 4, 27	12
33	Coronavirus disease 2019 (COVID-19): latest developments in potential treatments. 2020 , 9,	10
32	Identification of Berbamine, Oxyacanthine and Rutin from Berberis asiatica as anti-SARS-CoV-2 compounds: An in silico study. 2021 , 109, 108028	4
31	Induced Pluripotent Stem Cell Derived Human Lung Organoids to Map and Treat the SARS-CoV2 Infections In Vitro. 2021 , 1312, 1-17	
30	A Review of the Novel Corona Virus Disease (2019-nCoV). 2020 , 5, 180-187	
29	Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies.	2
28	Whey-Derived Peptides at the Heart of the COVID-19 Pandemic. 2021 , 22,	0
27	Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent. 2020 , 11, 85-104	
26	Similarities & Correspondences of novel coronavirus (CoV), SARS and MERS in KSA. 2020 , 6, 75-82	

25 Coronavirus and Homo Sapiens.

24 Clinical Manifestations of Patients with Coronavirus Disease 2019 (COVID-19) in a Referral Center in Iran. **2020**, 19, 122-128 1

23 The COVID-19 pandemic and the potential treatment of the novel coronavirus SARS-CoV-2. **2021**, 13, 871-881

22 The potential of drug delivery nanosystems to treat COVID-19. **2022**, 307-337

21 The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies. **2021**, 12, 704205 13

20 Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment. **2021**, 12, 732403 2

19 A Narrative Review of Existing Options for COVID-19-Specific Treatments. **2021**, 2021, 8554192

18 Coronavirus Disease-2019 and its current Scenario - A Review. **2021**, 4, 67-67 1

17 Chapter 10:Repurposing Approved Drugs to Block Highly Pathogenic Emerging Viruses. **2021**, 232-255

16 Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19.. **2022**, 27, 13596535221082773 0

15 An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- α and hydroxychloroquine in hospitalized patients with COVID-19 [Final results from the DisCoVeRy trial. 0

14 Therapeutic strategies for COVID-19 patients: An update.. **2022**,

13 Does Losartan reduce the severity of COVID-19 in hypertensive patients?. **2022**, 22, 116 0

12 Inhibition of the IFN- α /JAK/STAT Pathway by MERS-CoV and SARS-CoV-1 Proteins in Human Epithelial Cells.. **2022**, 14, 0

11 Recent advances in understanding SARS-CoV-2 infection and updates on potential diagnostic and therapeutics for COVID-19. **2022**, 03,

10 In Silico Multi-Target Approach Revealed Potential Lead Compounds as Scaffold for the Synthesis of Chemical Analogues Targeting SARS-CoV-2.. **2022**, 11, 1

9 COVID-19 Overview, Natural Immune-Boosting Medication, and The Economic Implication. **2022**, 5, 0

8 Drug Repurposing Techniques in Viral Diseases.

- 7 Corona Virus Disease (COVID-19): A past and Present Prospective. **2022**, 45-53
- 6 Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates.. **2022**, 27, 3
- 5 Potential drugs in SARS-CoV-2 treatment. **2022**, 59-71 0
- 4 Identification of SARS-CoV-2 spike protein inhibitors from urtica dioica to develop herbal-based therapeutics against COVID-19. **2022**, 0 0
- 3 Heterogeneity of treatment effect of interferon- β and lopinavir/ritonavir in patients with Middle East respiratory syndrome by cytokine levels. **2022**, 12, 0
- 2 The efficacy of Zafirlukast as a SARS-CoV-2 Helicase Inhibitor in Adult Patients with moderate COVID-19 Pneumonia (Pilot Randomized Clinical Trial). **2022**, 0
- 1 Mortality and Survival Factors in Patients with Moderate and Severe Pneumonia Due to COVID-19. **2023**, 11, 932 0